SPRC

NASDAQ Healthcare

SciSparc Ltd. - Ordinary Shares

Biotechnology

SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution. The company sells hemp seed oil-based products and others. The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and palmitoylethanolamide oral tablets CannAmide in softgel capsule form. It also has an agreement with The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation; and a collaboration with Clearmind Medicine Inc. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel.

๐ŸŽฏ Investment Strategy Scores

SPRC scores across each investment strategy. Higher is better for that strategy's goals.

High dividend yield + low volatility
๐Ÿš€ Moon Shot 94/100โ–ฒ +2
High growth potential (high beta + oversold)
๐Ÿ”ช Falling Knife 97/100โ–ฒ +6
Contrarian plays (oversold + below moving average)
๐ŸŽˆ Over-Hyped 75/100โ–ผ -12
Overbought stocks (potential short candidates)
๐Ÿ” Strategy Interpretation

Best fit: ๐Ÿ”ช Falling Knife (97/100) โ€” this strategy Contrarian plays (oversold + below moving average).

Lowest fit among scored strategies: ๐Ÿ’ฐ Dividend Daddy (3/100). No single score is a buy or sell signal โ€” use multiple lenses together. Learn how to read these scores โ†’

Find SPRC in your text

Paste any article, transcript, or post โ€” the tool will extract SPRC and every other hidden ticker.

Try the Ticker Extractor โ†’

Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-06-02.